









Markets
/
Stocks
/
nasdaq-slgl
/

Sol Gel Technologies Ltd

SLGL

30.500USD

+3.932+14.80%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

84.97MMarket Cap

LossP/E TTM



Sol Gel Technologies Ltd

30.500

+3.932+14.80%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a . Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

209 / 506

Overall Ranking

334 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

60.000

Target Price

+677.71%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Sol-Gel Technologies Ltd is a clinical-stage dermatology company. The Company is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company’s offers a range of products twins, sirs-t, and vered. The Company is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 197.14% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 11.54M.

Fairly Valued

The company’s latest PE is -11.57, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 2.50M shares, decreasing 4.02% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 0.00 shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 6.23, which is lower than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 17.26M, representing a year-over-year increase of 217.71%, while its net profit experienced a year-over-year increase of 487.55%.

Score

Industry at a Glance

Previous score

6.23

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

4.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.10

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.03

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -10.08, which is -30.98% below the recent high of -6.96 and -63.47% above the recent low of -16.48.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 209/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

There is no earnings forecast score for this company; the Biotechnology & Medical Research industry's average is 8.03. The average price target for Sol Gel Technologies Ltd is 60.00, with a high of 60.00 and a low of 60.00.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 8.67, which is higher than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 31.41 and the support level at 20.31, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.67

Change

0.44

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(1)

Buy(4)

Indicators

Value

Direction

MACD(12,26,9)

-0.172

Neutral

RSI(14)

72.810

Buy

STOCH(KDJ)(9,3,3)

67.080

Buy

ATR(14)

2.551

High Vlolatility

CCI(14)

160.244

Buy

Williams %R

5.371

Overbought

TRIX(12,20)

1.727

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

25.910

Buy

MA10

25.587

Buy

MA20

24.637

Buy

MA50

17.614

Buy

MA100

12.494

Buy

MA200

9.697

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 7.00, which is higher than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 89.88%, representing a quarter-over-quarter increase of 6.24%. The largest institutional shareholder is Invesco, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 1.00% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

M.Arkin Dermatology, Ltd.

1.81M

Phoenix Investment and Finances Ltd

247.02K

Arkin (Moshe)

143.26K

+275.67%

Migdal Insurance and Financial Holdings Ltd

122.75K

Yelin Lapidot Provident Funds Management Ltd

22.71K

Raymond James Financial Services Advisors, Inc.

8.68K

+3.72%

UBS Financial Services, Inc.

3.81K

+79.16%

Morgan Stanley & Co. LLC

9.24K

+4.67%

Raymond James & Associates, Inc.

2.51K

-0.59%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.05, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 1.26. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.